List of Excipients in API deutetrabenazine
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing deutetrabenazine
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| Teva Neuroscience Inc | AUSTEDO | deutetrabenazine | 68546-170 | AMMONIA | 2034-03-18 |
| Teva Neuroscience Inc | AUSTEDO | deutetrabenazine | 68546-170 | BUTYL ALCOHOL | 2034-03-18 |
| Teva Neuroscience Inc | AUSTEDO | deutetrabenazine | 68546-170 | BUTYLATED HYDROXYANISOLE | 2034-03-18 |
| Teva Neuroscience Inc | AUSTEDO | deutetrabenazine | 68546-170 | BUTYLATED HYDROXYTOLUENE | 2034-03-18 |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Detailed excipient profiles for deutetrabenazine
Excipient focus: AMMONIA
deutetrabenazine drug variants containing AMMONIA
| Company | Ingredient | NDC |
|---|---|---|
| Teva Neuroscience Inc | deutetrabenazine | 68546-170 |
| >Company | >Ingredient | >NDC |
deutetrabenazine drug variants not containing AMMONIA
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: BUTYL ALCOHOL
deutetrabenazine drug variants containing BUTYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| Teva Neuroscience Inc | deutetrabenazine | 68546-170 |
| >Company | >Ingredient | >NDC |
deutetrabenazine drug variants not containing BUTYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: BUTYLATED HYDROXYANISOLE
deutetrabenazine drug variants containing BUTYLATED HYDROXYANISOLE
| Company | Ingredient | NDC |
|---|---|---|
| Teva Neuroscience Inc | deutetrabenazine | 68546-170 |
| >Company | >Ingredient | >NDC |
deutetrabenazine drug variants not containing BUTYLATED HYDROXYANISOLE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: BUTYLATED HYDROXYTOLUENE
deutetrabenazine drug variants containing BUTYLATED HYDROXYTOLUENE
| Company | Ingredient | NDC |
|---|---|---|
| Teva Neuroscience Inc | deutetrabenazine | 68546-170 |
| >Company | >Ingredient | >NDC |
deutetrabenazine drug variants not containing BUTYLATED HYDROXYTOLUENE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: CELLULOSE, MICROCRYSTALLINE
deutetrabenazine drug variants containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| Teva Neuroscience Inc | deutetrabenazine | 68546-170 |
| >Company | >Ingredient | >NDC |
deutetrabenazine drug variants not containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FD&C BLUE NO. 2
deutetrabenazine drug variants containing FD&C BLUE NO. 2
| Company | Ingredient | NDC |
|---|---|---|
| Teva Neuroscience Inc | deutetrabenazine | 68546-170 |
| >Company | >Ingredient | >NDC |
deutetrabenazine drug variants not containing FD&C BLUE NO. 2
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FD&C RED NO. 40
deutetrabenazine drug variants containing FD&C RED NO. 40
| Company | Ingredient | NDC |
|---|---|---|
| Teva Neuroscience Inc | deutetrabenazine | 68546-170 |
| >Company | >Ingredient | >NDC |
deutetrabenazine drug variants not containing FD&C RED NO. 40
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERROSOFERRIC OXIDE
deutetrabenazine drug variants containing FERROSOFERRIC OXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Teva Neuroscience Inc | deutetrabenazine | 68546-170 |
| >Company | >Ingredient | >NDC |
deutetrabenazine drug variants not containing FERROSOFERRIC OXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MAGNESIUM STEARATE
deutetrabenazine drug variants containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| Teva Neuroscience Inc | deutetrabenazine | 68546-170 |
| >Company | >Ingredient | >NDC |
deutetrabenazine drug variants not containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MANNITOL
deutetrabenazine drug variants containing MANNITOL
| Company | Ingredient | NDC |
|---|---|---|
| Teva Neuroscience Inc | deutetrabenazine | 68546-170 |
| >Company | >Ingredient | >NDC |
deutetrabenazine drug variants not containing MANNITOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYETHYLENE GLYCOL
deutetrabenazine drug variants containing POLYETHYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| Teva Neuroscience Inc | deutetrabenazine | 68546-170 |
| >Company | >Ingredient | >NDC |
deutetrabenazine drug variants not containing POLYETHYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYETHYLENE GLYCOL 2000000
deutetrabenazine drug variants containing POLYETHYLENE GLYCOL 2000000
| Company | Ingredient | NDC |
|---|---|---|
| Teva Neuroscience Inc | deutetrabenazine | 68546-170 |
| >Company | >Ingredient | >NDC |
deutetrabenazine drug variants not containing POLYETHYLENE GLYCOL 2000000
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYSORBATE 80
deutetrabenazine drug variants containing POLYSORBATE 80
| Company | Ingredient | NDC |
|---|---|---|
| Teva Neuroscience Inc | deutetrabenazine | 68546-170 |
| >Company | >Ingredient | >NDC |
deutetrabenazine drug variants not containing POLYSORBATE 80
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYVINYL ALCOHOL
deutetrabenazine drug variants containing POLYVINYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| Teva Neuroscience Inc | deutetrabenazine | 68546-170 |
| >Company | >Ingredient | >NDC |
deutetrabenazine drug variants not containing POLYVINYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POVIDONE
deutetrabenazine drug variants containing POVIDONE
| Company | Ingredient | NDC |
|---|---|---|
| Teva Neuroscience Inc | deutetrabenazine | 68546-170 |
| >Company | >Ingredient | >NDC |
deutetrabenazine drug variants not containing POVIDONE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: PROPYLENE GLYCOL
deutetrabenazine drug variants containing PROPYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| Teva Neuroscience Inc | deutetrabenazine | 68546-170 |
| >Company | >Ingredient | >NDC |
deutetrabenazine drug variants not containing PROPYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SHELLAC
deutetrabenazine drug variants containing SHELLAC
| Company | Ingredient | NDC |
|---|---|---|
| Teva Neuroscience Inc | deutetrabenazine | 68546-170 |
| >Company | >Ingredient | >NDC |
deutetrabenazine drug variants not containing SHELLAC
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TALC
deutetrabenazine drug variants containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| Teva Neuroscience Inc | deutetrabenazine | 68546-170 |
| >Company | >Ingredient | >NDC |
deutetrabenazine drug variants not containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TITANIUM DIOXIDE
deutetrabenazine drug variants containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Teva Neuroscience Inc | deutetrabenazine | 68546-170 |
| >Company | >Ingredient | >NDC |
deutetrabenazine drug variants not containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
© Copyright 2002-2024 thinkBiotech LLC
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Preferred Citation:
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Links
Follow DrugPatentWatch:
